Deutetrabenazine

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.

VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.

Journal: CNS spectrums

Published: October 22, 2025

Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.

Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.

Journal: Journal of managed care & specialty pharmacy

Published: September 12, 2025

Refractory tardive dyskinesia in the critical care setting: A case report of successful use of phenobarbital.

Refractory tardive dyskinesia in the critical care setting: A case report of successful use of phenobarbital.

Journal: SAGE open medical case reports

Published: August 04, 2025

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington's Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Journal: Medical sciences (Basel, Switzerland)

Published: August 01, 2025

A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.

A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.

Journal: Medicine

Published: June 09, 2025

Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis.

Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis.

Journal: Frontiers in pharmacology

Published: May 29, 2025

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.

Journal: Tremor and other hyperkinetic movements (New York, N.Y.)

Published: April 04, 2025

Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis.

Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis.

Journal: Journal of Huntington's disease

Published: March 24, 2025

Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis.

Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis.

Journal: Neurology

Published: February 27, 2025

A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults.

Journal: Medicine

Published: February 19, 2025

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets.

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets.

Journal: Progress in molecular biology and translational science

Published: February 13, 2025

From assessment to intervention: evidence-based approaches in tardive dyskinesia.

From assessment to intervention: evidence-based approaches in tardive dyskinesia.

Journal: CNS spectrums

Published: February 12, 2025

Showing 1-12 of 171

Last Updated: 02/24/2026